Pfizer (PFE) Granted FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for Treatment of Active Psoriatic Arthritis
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved XELJANZ® 5 mg ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
